During the last three months, 20 analysts shared their evaluations of Kimberly-Clark KMB, revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 4 | 11 | 2 | 1 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 2 | 9 | 2 | 1 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $140.15, a high estimate of $165.00, and a low estimate of $115.00. Surpassing the previous average price target of $129.56, the current average has increased by 8.17%.
Investigating Analyst Ratings: An Elaborate Study
In examining recent analyst actions, we gain insights into how financial experts perceive Kimberly-Clark. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Kevin Grundy | Exane BNP Paribas | Announces | Neutral | $146.00 | - |
| Nik Modi | RBC Capital | Maintains | Outperform | $165.00 | $165.00 |
| Anna Lizzul | B of A Securities | Raises | Buy | $160.00 | $115.00 |
| Nik Modi | RBC Capital | Raises | Outperform | $165.00 | $126.00 |
| Lauren Lieberman | Barclays | Raises | Equal-Weight | $136.00 | $132.00 |
| Filippo Falorni | Citigroup | Raises | Sell | $125.00 | $111.00 |
| Anna Lizzul | B of A Securities | Raises | Underperform | $115.00 | $110.00 |
| Nik Modi | RBC Capital | Raises | Sector Perform | $126.00 | $123.00 |
| Alejandro Zamacona | HSBC | Raises | Hold | $150.00 | $146.00 |
| Peter Grom | UBS | Raises | Neutral | $138.00 | $135.00 |
| Andrea Teixeira | JP Morgan | Raises | Underweight | $123.00 | $115.00 |
| Chris Carey | Wells Fargo | Raises | Equal-Weight | $136.00 | $131.00 |
| Jason English | Goldman Sachs | Raises | Buy | $152.00 | $135.00 |
| Lauren Lieberman | Barclays | Raises | Equal-Weight | $132.00 | $124.00 |
| Steve Powers | Deutsche Bank | Raises | Hold | $132.00 | $127.00 |
| Korinne Wolfmeyer | Piper Sandler | Raises | Overweight | $152.00 | $145.00 |
| Nik Modi | RBC Capital | Maintains | Sector Perform | $123.00 | - |
| Chris Carey | Wells Fargo | Raises | Equal-Weight | $131.00 | $125.00 |
| Javier Escalante | Evercore ISI Group | Raises | Outperform | $150.00 | $133.00 |
| Alejandro Zamacona | HSBC | Raises | Hold | $146.00 | $134.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Kimberly-Clark. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Kimberly-Clark compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Kimberly-Clark's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Kimberly-Clark analyst ratings.
About Kimberly-Clark
With more than half of sales from personal care and another third from consumer tissue products, Kimberly-Clark sits as a leading manufacturer in the tissue and hygiene realm. Its brand mix includes Huggies, Scott, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary offerings for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest predominantly concentrated in Asia and Latin America.
Kimberly-Clark's Economic Impact: An Analysis
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Challenges: Kimberly-Clark's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -0.89%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Staples sector.
Net Margin: Kimberly-Clark's net margin is impressive, surpassing industry averages. With a net margin of 12.57%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Kimberly-Clark's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 66.05% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 3.76%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 7.63.
The Significance of Analyst Ratings Explained
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
